📰 Acticor News
Page 2 - Acticor News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Acticor. Real-time updates on events, politics, business and more.
November 22, 2022
Regulatory News: Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug
October 27, 2022
Significant clinical progress in the treatment of stroke with glenzocimab: Positive results from the ACTIMIS phase 1b/2a study Patent granted to protect glenzocimab in thrombotic
September 26, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke
September 9, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today
June 29, 2022
This patent protects the use of glenzocimab in thrombotic diseases until 2036 This patent has already been granted in the United States and Singapore and is in the process of being granted
June 7, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies
May 9, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies,announces today the
May 4, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies
April 27, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, announces
March 30, 2022
Successful IPO on Euronext Growth in Paris Cash position of €11.3 million at 31 December 2021 Promising clinical results with the continuing development of glenzocimab for use in stroke Regulatory